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Abstract: Since their initial availability in 1997, the thiazolidinediones (TZDs) have become 
one of the most commonly prescribed classes of medications for type 2 diabetes. In addition 
to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and 
non-traditional risk factors for diabetes. TZDs may beneﬁ  t cardiovascular parameters, such as 
lipids, blood pressure, inﬂ  ammatory biomarkers, endothelial function and ﬁ  brinolytic state. In 
this review, we summarise the experimental, preclinical and clinical data regarding the effects 
of the TZDs in conditions for which they are indicated and discuss their potential in the treat-
ment of other conditions.
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Introduction
Thiazolidinediones (TZDs) agonists for peroxisome proliferators-activated recep-
tor (PPAR) γ are currently used therapeutically. Troglitazone, the ﬁ  rst agent of this 
class to be approved, was effective in controlling glycemia but was removed from 
the market because of serious liver toxicity. Pioglitazone and Rosiglitazone are 
PPARγ agonists currently licensed for the management of hyperglycemia in Type 
2 diabetes mellitus (T2DM). TZDs induced glycemic improvement is accompanied 
by a signiﬁ  cant reduction in fasting insulin. The magnitude of the improvement 
depends on many factors such as body mass index (BMI), basal glucose levels, the 
degree of insulin resistance and the extent of β-cell failure. Interestingly, TZDs 
may beneﬁ  t cardiovascular parameters, such as lipids, blood pressure, inﬂ  amma-
tory biomarkers, endothelial function and ﬁ  brinolytic state (Parulkar et al 2001; 
Haffner et al 2002). Moreover, they have been successfully used in non-diabetic 
insulin resistant conditions such as polycystic ovary syndrome (Romualdi et al 
2003; Glintborg et al 2005).
The purpose of this review is to give a timely examination of the efﬁ  cacy of PPARγ 
agonists in conditions for which they are currently indicated and discuss their potential 
in the treatment of other conditions.
Mechanism of action and insulin resistance
The mechanism of action of thiazolidinediones involves their binding to the nuclear 
PPARγ receptor. PPARγ is a nuclear receptor that acts as a transcription factor upon 
activation, by regulating the transcription and expression of speciﬁ  c genes. Together 
with the isoforms PPAR-α and PPAR-δ, is a member of a family of nuclear hormone 
receptors that includes the retinoid X receptor (RXR), the vitamin D receptor and the 
thyroid hormone receptor. PPARs play a critical role as lipid sensors and regulators 
of lipid metabolism.Vascular Health and Risk Management 2008:4(2) 298
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PPARs seem to regulate gene transcription by two 
mechanisms (Figure 1). Transactivation, a DNA-dependent 
mechanism that involves binding to PPAR response elements 
of target genes (see below) and a second mechanism, 
transrepression, that would explain the anti-inﬂ  ammatory 
actions of PPARs. It involves interfering with other 
transcription-factor pathways in a DNA-independent way 
(Jarvinen 2004).
PPAR-α is principally expressed in tissues that exhibit a 
high rate of fatty acid metabolism (eg, brown adipose tissue, 
liver, kidney and heart) and is the molecular target for the 
ﬁ  brate class of drugs (Willson et al 2000). Less is known 
about the physiological roles of PPAR-δ, which is expressed 
more ubiquitously, although recent studies have implicated 
it in lipid trafﬁ  cking in macrophages and trophoblast (Oliver 
et al 2001; Chawla et al 2003), blastocyst implantation (Lim 
and Dey 2000), wound healing (Tan et al 2001), and the 
regulation of fatty acid catabolism and energy homeostasis 
(Peters et al 2000; Wang et al 2003). PPAR-γ is mainly found 
in adipose tissue, intestinal cells and macrophages, although 
it is also expressed in other tissues including skeletal muscle 
and endothelium at lower concentrations (Perry and Petrie 
2002).
On ligand binding, the PPAR forms a heterodimer with 
the RXR and they bind to speciﬁ  c peroxisome proliferators 
response elements (PPRE) on a number of key target genes 
involved in the carbohydrate and lipid metabolism. Endog-
enous ligands of PPAR-γ include long chain unsaturated fatty 
acids and prostanoids (Shiraki et al 2005). Insulin resistance 
is caused by multiple factors, most likely involving many 
Figure 1 Molecular mechanisms of Thiazolidinediones. In transactivations, perozisome-proliferator-activated receptor γ (PPARγ) is a nuclear receptor that acts as a tran-
scription factor upon activation. Thiazolidinediones can active PPARγ. On ligand binding, the PPAR forms a heterodimer with the retinoid X receptor (RXR) and they bind to 
speciﬁ  c peroxisome proliferators response elements (PPRE) on a number of key target genes involved in the carbohydrate and lipid metabolism. In transespression PPARs 
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different aspects of the metabolic regulation of insulin in 
muscle, liver and adipose tissue.
Current evidence supports the notion that the primary 
target tissue of TZDs is the adipose tissue. Their effect on 
insulin-stimulated glucose disposal may in part be secondary 
to changes in adipose tissue, where PPAR-γ is predominantly 
expressed, and involve factors that alter peripheral insulin 
sensitivity. TZDs have been shown to selectively stimulate 
lipogenic activities in fat cells resulting in greater insulin 
suppression of lipolysis (Oakes et al 2001). They decrease 
FFAs available for inﬁ  ltration into other tissues; thus TZDs 
treatment target the insulin-desensitizing effects of FFAs 
in muscle and liver (Vasudevan and Balasubramanyam 
2004). Finally, TZDs have been shown to alter expression 
and release of adipokines. Resistin and TNF-α, which have 
the potential to decrease insulin sensitivity, are reduced 
following incubation with TZDs (Steppan et al 2001: 
Hofmann et al 1994; De Vos et al 1996). Conversely, the 
level of adiponectin is increased after TZD treatment in vitro 
(Maeda et al 2001). Additionally, TZDs enhance the lipid 
storage capacity of adipose tissue by increasing the number 
of small adipocytes. This lipogenic effect may lead to a 
reduction of deleterious lipid accumulation in other insulin-
sensitive tissues such as the muscle and liver, thus reducing 
insulin resistance (Okuno et al 1998).
The TZDs therefore hold promise as agents that 
can ameliorate insulin resistance due to lipotoxicity in 
obesity- and lipodystrophy-associated T2DM (Unger and 
Orci 2001).
Clinical effects
The TZDs have been shown to mediate a variety of effects 
on the complex pathophysiology associated with insulin 
resistance (Bhatia and Viswanathan 2006) (Figure 2).
They are now approved for the treatment of T2DM and 
offer a new angle of attach in the pharmacologic management 
of T2DM.
Unlike other oral antidiabetic agents, TZDs are unique 
because they improve insulin sensitivity by increas-
ing insulin-mediated glucose uptake in skeletal muscle, 
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suppressing hepatic glucose output and improving the secretory 
response of insulin in pancreatic β-cells (Camp 2003).
The TZDs are indicated in the United States for 
monotherapy and as combination therapy with sulfonylureas, 
metformin and insulin for treatment of T2DM (Diamant and 
Heine 2003).
Rosiglitazone and pioglitazone are the only TZDs 
available for clinical uses.
As monotherapies, both agents signiﬁ  cantly improve 
insulin sensitivity and glycemic control in T2DM patients 
by decreasing plasma glucose and plasma insulin levels, 
thus reducing HbA1c levels from 0.5% to 1.9% (Lebovitz 
et al 2001; Miyazaki et al 2001). In combination therapy 
with other oral diabetes medications, both rosiglitazone and 
pioglitazone demonstrate additive effects on glycemic control 
compared with monotherapy (Camp 2003).
Effect of adipocytes and serum 
lipid proﬁ  le
The typical lipid proﬁ  le of T2DM is characterized by low 
HDL, hypertriglyceridemia, and degeneration of atherogenic, 
small, dense LDL-cholesterol particles which are prone to oxi-
dation and glication (Ginsberg et al 2005). Pioglitazone have 
beneﬁ  cial effects in attenuating this complex dyslipidemic 
states. Typical beneﬁ  cial effects in attenuating this complex 
dyslipidemic state have been described in studies using piogli-
tazone (Einhorn et al 2000; Rosenstck et al 2002) and rosigli-
tazone (Patel et al 1999; Raskin et al 2000; Fhillips et al 2001). 
Data for rosiglitazone, in combination with metformin for 26 
weeks showed an HDL increase of 13.3%, LDL increase of 
18.6% and a neutral effect on total cholesterol (Fonseca et al 
2000). A study reported by Khan et al found that pioglitazone 
was superior to rosiglitazone in terms of lowering triglyceride 
(TG) and total cholesterol (TC) in T2DM patients (Khan et al 
2002). By modulating adipogenic differentiation, the in vivo 
effects of TZDs on lipid proﬁ  le may be do to the repartitioning 
of lipids. Studies in human tissue point to a critical role for 
PPARγ in the regulation of adipogenesis. Exposure of human 
pre-adipocytes to TZDs induces differentiation (Adams et al 
1997). Intriguingly, pre-adipocytes isolated from subcutane-
ous abdominal adipose tissue have been shown to differentiate 
more readily in response to TZDs than from visceral depots 
taken from the same subjects (Adams et al 1997).
Evidence emerging from studies of humans and mice has 
indicated PPARγ to be not only a key factor for adipogenesis 
but also a critical determinant of body fat distribution (Tsai 
and Maeda 2005). In patients with T2DM studied by com-
puterized tomography, visceral adipose tissue decreased 
following TZDs treatment while subcutaneous adipose tissue 
increased (Mori et al 1999).
These ﬁ  ndings correlate with the adipogenic effects of 
TZDs used in clinical practice; treated type 2 diabetic patients 
accumulate subcutaneous fat, whereas visceral adipose tissue 
volume is reduced or unchanged (Bays et al 2004). It is well-
established that subcutaneous adipose tissue is metabolically 
less harmful than visceral adipose tissue (Montague et al 2000). 
This may, in part, explain the beneﬁ  cial effects of TZDs despite 
their tendency to induce weight gain (Bays et al 2004).
Effect on inﬂ  ammation 
and atherosclerosis
Atherogenesis is believed to be initiated by passage of lipid 
through the vascular endothelium, and deposition in the arte-
rial intima, where it stimulates an inﬂ  ammatory response. 
The anti-inﬂ  ammatory properties of TZDs, in addition to 
their metabolic effects, may confer further cardiovascular 
beneﬁ  ts (Blaschke et al 2006).
PPARγ agonists have been shown to reduce endothelial 
expression of VCAM-1 (Pasceri et al 2001) and intercellular 
adhesion molecule-1 (Wang et al 2002) on activated endo-
thelium. Thus TZDs, through modulating inﬂ  ammation, may 
inﬂ  uence the early stages of atherosclerosis.
The subsequent immune response, monocyte chemotaxis, 
T-cell activation and vascular smooth cell migration, forms 
the atherosclerotic plaque. It was recently demonstrated that 
pioglitazone and rosiglitazone have direct anti-inﬂ  ammatory 
effects in a rat model of atherosclerosis via interference with 
monocyte chemoattractant protein 1 and its monocyte recep-
tor (CCR2) (Ishibashi et al 2002; Han et al 2000).
As monocytes enter in the intima they undergo transfor-
mation into macrophages. They take up lipid deposited in the 
intima forming the “foam cells”. Foam cells may play a pivotal 
role in atherogenesis, secreting reactive oxygen species and 
inﬂ  ammatory cytokines. PPARγ is upregulated in activated 
macrophages while PPARγ agonists have been shown to 
attenuate the inﬂ  ammatory response in activated monocytes 
and macrophages. Thus, activation of PPARγ receptors in 
macrophages within the arterial intima may reduce cytokine 
production, limiting the local inﬂ  ammatory response, hence 
arresting atherosclerosis (see below) (Roberts et al 2003).
Effect on endothelial dysfunction 
and blood pressure
The TZDs have salutary effects on endothelial dysfunction, 
a key factor in the pathogenesis of cardiovascular disease 
(Widlansky et al 2003). Endothelium-derived nitric oxide Vascular Health and Risk Management 2008:4(2) 301
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(NO) is responsible for vasodilatation, and No- synthase 
(eNOS) expression, is diminished in diabetic patients. It has 
been shown that TZDs up-regulates eNOS expression (Goya 
et al 2006). Expression of endothelin-1 (ET-1), a potent 
endothelial-derived vasoconstrictor compound, thought to be 
involved in the pathogenesis of numerous complications of dia-
betes, is regulated by TZDs action (Hopfner and Gopalakrish-
nan 1999). In a randomized study rosiglitazone was shown to 
improve endothelial dysfunction (Natali et al 2002).
TZDs are also able to exert direct beneﬁ  cial vascular 
effects beyond their effect on glycemia, thus reducing 
cardiovascular risk in type 2 diabetics. For example, 
rosiglitazone has been reported to increase differentiation 
towards the endothelial lineage when treating a hetero-
geneous population of angiogenic precursors, an effect 
mediated by PPAR-γ (Wang et al 2004)
Twelve-week treatment with rosiglitazone improved 
endothelial progenitor cells (EPC) number and migratory 
activity of T2DM patients (Pistrosch et al 2005).
Also pioglitazone was demonstrated to have a PPAR-γ 
dependent stimulation effect on EPCs (Redondo et al 2007).
Some observations strongly suggest that insulin resistance 
per se is related to endothelial dysfunction, independent 
of glycemic control, and that rosiglitazone has therapeutic 
effects on this endothelial dysfunction (Pistrosch et al 2004). 
Interestingly, these endothelium-related effects are observed 
even in non-diabetic subjects (Horio et al 2005).
Studies conducted on mammalian models of diabetes 
suggest that TZDs may be useful in the treatment of hyper-
tension, particularly when associated with insulin resistance 
(Grinsell et al 2000; Diep et al 2002; Schiffrin et al 2003). 
Bakris et al demonstrated signiﬁ  cant reduction in systolic, 
diastolic and mean arterial blood pressure after 52 week 
of rosiglitazone treatment (Bakris et al 2000). In another 
study, decreases in mean arterial blood pressure with the 
use of troglitazone correlated signiﬁ  cantly with reductions 
in plasma insulin, suggesting a link between improvement of 
insulin sensitivity and blood pressure reduction (Ogihara et al 
1995). ET-1 is a potent vasoconstrictor, as well as a mediator 
of smooth muscle mitogenesis, and thus a determinant of 
systemic blood pressure (Miller et al 1993). TZDs treatment 
has been shown to attenuate the release of ET-1 from vascular 
cells, which may contribute to the observed blood pressure 
lowering effect (Satoh et al 1999; Iglarz M et al 2003).
Use in diabetes prevention
Insulin resistance is the key mechanism underlying impaired 
glucose tolerance (IGT) (Turner and Clapham 1998). 
Three large-scale intervention trials have demonstrated the 
beneﬁ  cial effect of weight reduction, dietary modiﬁ  cations 
and regular exercise on IGT (Pan et al 1997; Knowler et al 
2002; Tuomilehto et al 2001). The overall risk that patients 
with IGT will develop diabetes is 3–9% per year in the 
United States (Ipp 2000). TZDs improve insulin sensitivity 
in a range of insulin-resistant states without diabetes, includ-
ing obesity and IGT (Ghanim et al 2001; Sekino et al 2003; 
Bennett et al 2004).
Durbin et al studied 172 IGT patients and demonstrated 
that the incidence of diabetes after three years was 88.9% 
lower in the TZD’s treated group compared with the control 
group (Durbin 2004).
The pivotal problem of progression to overt diabetes 
from a prediabetic state is impaired β-cell function to begin 
with decline due to glucolipotoxicity; β-cell is unable to 
meet the insulin requirements imposed by insulin resistance 
The TRIPOD Study (Troglitazone in the Prevention of 
Diabetes Mellitus) (Buchanan et al 2002) was a double blind 
prospective, randomized, placebo controlled, study examin-
ing Hispanic women without diabetes but with previous 
gestational diabetes. In this study troglitazone had a sustained 
beneﬁ  cial effect on β-cell function in addition to the insulin-
sensitizing and glucose lowering properties still present 8 
months after discontinuation of the medication. The admin-
istration of troglitazone reduced the incidence of diabetes by 
50% in high-risk women. All these data strongly advocate a 
role of this class of drugs in the prevention of T2DM.
Safety
The TZDs are generally safe and well tolerated. The liver 
toxicity that resulted in withdrawal of troglitazone from 
market does not seem to be a problem with rosiglitazone 
and pioglitazone (Scheen 2001). The incidence of liver 
toxicity occurred in approximately one in 100000 patients 
(Tolman 2000; Parulkar et al 2001). There is no clear 
molecular explanation for this adverse effect, however, it 
was reported that troglitazone, unique among the TZDs, 
activates the pregnane X receptor, a transcription factor that 
induces the expression of the hepatic cytochrome P450 3A4 
gene (Kliewer et al 1999; Lehmann et al 1998). Following 
the withdrawal of troglitazone, the liver enzyme levels of 
patients prescribed rosiglitazone or pioglitazone have been 
carefully monitored, and no increase in TZD-induced liver 
toxicity has been reported.
The TZDs have been associated with weight gain of 
3–5 Kg in a dose-dependent manner, most likely due to an 
increase in fat mass, peripheral edema or both. In particular Vascular Health and Risk Management 2008:4(2) 302
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the weight gain noted with TZD therapy may actually be 
associated with a beneﬁ  cial redistribution of fat between the 
visceral versus subcutaneous body compartments (Nakamura 
et al 2001; Nesto et al 2003). Visceral adipose tissue is 
associated with the metabolic syndrome, being morphologi-
cally and functionally different from subcutaneous adipose 
tissue. Insulin effects trend to be blunted, and glucocorticoid 
and catecholamine effects trend to be enhanced in visceral 
adipose tissue compared with subcutaneous adipose tissue.
Fluid retention, expanded plasma volume and dependent 
edema have been noted with TZD therapy (Nesto et al 2003). In 
most of these cases, patients showed peripheral edema (swelling 
of legs, ankles, hands and face). In clinical practice, 3–5% of 
patients on either pioglitazone or rosiglitazone develop periph-
eral edema (Nesto et al 2003). The incidence of edema is much 
higher (up to 15%) in combination therapies that include insulin 
or sulfonylureas (Malinowski and Bolesta 2000). Although 
the precise mechanism underlying the edema are unclear, some 
studies have suggested a vascular leak syndrome, possibly due 
to increased concentrations of vascular permeability factors and 
enhancement of endothelial-mediated vasodilation (Emoto et al 
2001; Niemeyer and Janney 2002). Exacerbation of congestive 
heart failure (CHF) has rarely been reported with the use of 
TZDs (Nesto et al 2003). Because patients with advanced heart 
failure were not evaluated in clinical studies, TZDs are currently 
not recommended for use in individuals with New York Heart 
Association Class III or IV heart failure symptoms.
In their meta-analysis, Nissen and Wolski (2007) still 
suggest that rosiglitazone is associated with an increased risk 
of myocardial infarction. The main limitations of this study 
are the quality and quantity of the available data (Psaty and 
Furberg 2007). The mechanism for the apparent increase death 
from cardiovascular causes associated with rosiglitazone 
remains uncertain. One potential contributing factor may 
be a modest reduction in the hemoglobin level. In susceptible 
patients, a reducted hemoglobin level may result in increased 
physiological stress, thereby provoking myocardial ischemia. 
These data point to the urgent need for comprehensive evalu-
ations to clarify the cardiovascular risk of TZDs.
Future applications of PPAR 
agonists
TZD therapy appears to result in a variety of effects 
independent of blood glucose lowering which may have 
the potential to revolutionize the management of T2DM 
(Boden and Zhang 2006). Evidently, TZDs improve insulin 
sensitivity not only of T2DM but also of primarily non-
diabetic conditions. Theoretically, this opens the possibility 
of pharmacological prevention of T2DM and associated 
disease as strongly suggested by the sustained beneﬁ  cial 
effect in women with previous gestational diabetes (Stum-
voll 2003).
The anti-inﬂ  ammatory properties of the TZDs are par-
ticularly interesting in the context of atherosclerosis, now 
recognised to have a central inflammatory component. 
Their immunomodulatory and anti-inﬂ  ammatory effects 
may have a powerful impact on the cardiovascular disease 
burden associated with T2DM. There are some very recent 
results from the Prospective Pioglitazone Clinical Trial In 
Macrovascular Events (PROactive study). They show that 
pioglitazone reduces the occurrence of fatal and nonfatal 
myocardial infarction (MI) and acute coronary syndrome 
(ACS) (Erdmann et al 2007) and recurrent stroke (Wilcox 
et al 2007) in high-risk patients with T2DM. On the other 
hand, metabolic control as a surrogate endpoint did not 
demonstrate clinically relevant differences to the other oral 
antidiabetic drugs and the occurrence of edema was signiﬁ  -
cantly raised. Therefore, until new evidence becomes avail-
able, the beneﬁ  t-risk ratio of pioglitazone remains unclear 
(Richter et al 2006).
In ADOPT study is compared rosiglitazone with met-
formin and glyburide in terms of the duration of glycemic 
control. Recent data show a cumulative incidence of mono-
therapy failure at 5 years of 15% with rosiglitazone, 21% 
with metformin and 34% with glyburide (Kahn et al 2006).
The DREAM trial and related studies are determining 
if rapamil or rosiglitazone reduces the number of cases of 
diabetes and atherosclerosis, and are trying to identify novel 
risk factors for diabetes (DREAM Study 2004).
These and other large randomized studies are under way 
to evaluate this theme including, RECORD (Rosiglitazone 
evaluated for cardiac outcomes and regulation of glycemia in 
diabetes), ACCORD (Action to control cardiovascular risk in 
diabetes), PPAR (PPARg agonists for the prevention of late 
adverse events following percutaneous revascularisation).
Final results of these studies will shed light on effects 
of TZDs in treatment and prevention of insulin resistance, 
IGT and T2DM.
Abbreviations
T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes.
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